Literature DB >> 1357947

National guidelines for the management of asthma in adults.

R N Podell1.   

Abstract

Asthma is now considered primarily an inflammatory disease in which bronchospasm occurs secondary to airway inflammation. Management strategies include the use of inhaled anti-inflammatory agents, notably inhaled corticosteroids and cromolyn. Mild intermittent asthma may be treated with inhaled bronchodilators. Moderate asthma should be treated with an inhaled anti-inflammatory agent in addition to an inhaled beta agonist. If symptoms persist, an oral bronchodilator (either a beta-adrenergic agonist or theophylline) should be added. Therapy for severe asthma includes combinations of the foregoing medications, with the possible addition of oral corticosteroids. Other aspects of management include the use of a spacer device with inhaler therapy, control of concomitant allergies and triggering factors such as chronic sinusitis, tobacco smoke and gastroesophageal reflux, and home use of a portable peak flow meter to monitor the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357947

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

Review 1.  Cost effectiveness of leukotriene modifiers in adults with asthma.

Authors:  Pamela C Heaton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Knowledge of and reported asthma management among South Australian general practitioners.

Authors:  J R Coates; I D Steven; J Beilby; G Coffey; J C Litt; C Wagner
Journal:  Br J Gen Pract       Date:  1994-03       Impact factor: 5.386

3.  Outpatient management of asthma.

Authors:  M T Bowersox
Journal:  West J Med       Date:  1993-05

4.  AsthmaCritic: issues in designing a noninquisitive critiquing system for daily practice.

Authors:  Manon M Kuilboer; Marc A M van Wijk; Mees Mosseveld; Johan van der Lei
Journal:  J Am Med Inform Assoc       Date:  2003-06-04       Impact factor: 4.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.